daclizumab


Also found in: Wikipedia.

daclizumab

 [dah-kliz´u-mab]
an immunosuppressant used to prevent acute organ rejection in renal transplant patients; administered intravenously.

daclizumab

/da·cliz·u·mab/ (dah-kliz´u-mab) an immunosuppressant used to prevent acute organ rejection in renal transplant patients.

daclizumab

an immunosuppressant.
indications It is used to help prevent acute allograft rejection in renal transplant patients.
contraindications Known hypersensitivity to this drug contraindicates its use.
adverse effects Life-threatening effects are pulmonary edema, tachycardia, thrombosis, renal tubular necrosis, and hydronephrosis. Other adverse effects include headache, prickly sensation, coughing, atelectasis, congestion, constipation, abdominal pain, pyrosis, hypertension, bleeding, oliguria, dysuria, renal damage, and impaired wound healing. Common side effects include chills, tremors, dyspnea, wheezing, vomiting, nausea, and diarrhea.

daclizumab

Dacliximab, Zenapax® Transplant medicine A monoclonal antibody used with other agents to ↓ transplant-related GVHD and organ rejection in kidney and liver graft recipients, and Pts with treatment refractory psoriasis, uveitis, tropical spastic paraparesis and some leukemias. See Kidney transplant.

daclizumab

A humanized monoclonal antibody against the interleukin-2 receptor. It is used to decrease the risk of organ rejection in kidney and heart transplants.
References in periodicals archive ?
On the day of the procedure, they began receiving daclizumab (five doses of 1 mg/kg every 2 weeks) and etanercept (50 mg 1 hour after the procedure, followed by 25 mg on days 3, 7, and 10).
James Shapiro, MD and colleagues of the University of Alberta in Edmonton, Canada developed the experimental protocol, which involves injecting islet cells into the liver via the portal vein and preventing rejection using a 3-drug regimen of daclizumab plus low-dose tacrolimus and sirolimus.
Patient profiles for the eight DMAs in late clinical development (Aubagio, BG-12, alemtuzumab, PEG-Avonex, Copaxone 40mg 3x weekly, daclizumab, laquinimod, ocrelizumab) are also characterized.
The new Abbott compounds include daclizumab - a Phase II investigational biologic intended to treat multiple sclerosis that is expected to move into Phase III development in the second quarter 2010 - and oncology compounds in early- to mid-stage development that are being studied to treat different types of cancer, including multiple myeloma and chronic lymphocytic leukemia.
Facet and Biogen Idec have been working together to develop daclizumab for multiple sclerosis and volociximab for cancer since 2005.
a company that is developing the monoclonal antibody daclizumab along with Biogen Idec.
It is an IgG1 monoclonal antibody, that was approved several years ago for the prevention of renal allograft rejection, marketed under the name daclizumab.
But investigators at the University of Alberta, Edmonton, discarded the standard islet-toxic immunosuppressive regimen routinely used in whole-organ transplants in favor of a gentler sirolimus- and tacrolimus-based, corticosteroid-free regimen utilizing daclizumab, a monoclonal antibody directed against the interleukin-2 receptor on activated lymphocytes.
There were 2 deaths, 11 grade 1B rejections or greater, and no grade 3A rejections in the daclizumab group compared with 4 deaths, 16 grade 1B rejections or greater, and 5 grade 3A rejections among controls.
Together with emerging anti-CD25 MAb daclizumab (Biogen Idec/Abbott), emerging MAbs are expected to earn major-market sales of approximately $2 billion in 2021.
The compounds include daclizumab - a Phase II investigational biologic intended to treat multiple sclerosis (MS) that is expected to move into Phase III development in the second quarter 2010 - and oncology compounds in early- to mid-stage development.